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1. The identification of β-secretase as β-site amyloid
precursor protein cleaving enzyme (BACE)
Following the discoveries of β-amyloid (Aβ) and the first
amyloid precursor protein (APP) mutations that cause familial
Alzheimer’s disease (AD), it soon became clear that the β- and
γ-secretase enzymes were prime therapeutic targets for the
development of small-molecule inhibitor drugs for the treat-
ment of AD. Thus, their molecular identities were vigorously
pursued. The properties of Aβ generation and secretase activi-
ties in cells and tissues led to the development of cell-free
and cell-based assays that could be exploited for the identifi-
cation of the secretases. Subsequently, 5 groups independently
reported the molecular cloning of the β-secretase enzyme,
which they variously named BACE, Asp2, and memapsin 2.1–5
It is important to note that all the groups agreed on the same
polypeptide sequence even though they used different experi-
mental approaches to identify the β-secretase, lending strong
support for the conclusion that the authentic β-secretase had
been cloned.
BACE has all the molecular and cellular characteristics that
had been previously predicted for the β-secretase in vitro and
in vivo. It is a type I transmembrane aspartic protease of 501
amino acids in length that is closely related to the pepsin family
of aspartic proteases. The catalytic domain of BACE harbors 2
aspartic protease signature motifs of the sequence DTGS and
DSGT that come together to form the active site of the enzyme.
As required for β-secretase, the BACE active site is topologi-
cally oriented on the same side of the membrane as the
β-secretase cleavage site in APP. Additionally, the activity of
BACE has an acidic pH optimum and the catalytic domain
resides within the lumen of acidic intracellular compartments,
including endosomes and the trans-Golgi network. Moreover,
BACE levels are highest in neurons of the central nervous
system (CNS); BACE has the correct sequence specificity; and
BACE overexpressed in cells cleaves APP and increases Aβ
production.
Soon after the discovery of BACE, a homologue, BACE2,
was identified that has ~64% amino acid similarity to BACE
(henceforth referred to as BACE1). The extensive degree of
homology between the 2 enzymes suggested that BACE2 might
also function as a β-secretase. However, this possibility seemed
unlikely because BACE2 is not expressed to a high level in
neurons, in contrast to BACE1. Moreover, BACE2 predomi-
nantly cleaves APP within the Aβ domain, so that the genera-
tion of Aβ is precluded. These data, together with the finding
that BACE1-null mice are devoid of Aβ, suggest that BACE2 is
not likely to be a β-secretase in the CNS.
2. Physiological functions of BACE1
2.1. BACE1˗/˗ mice
To justify BACE1 inhibitor drug development efforts, it was
necessary to provide in vivo validation that BACE1 is the
primary β-secretase enzyme in the brain. To do so, gene target-
ing in embryonic stem cells was used to produce BACE1
knockout (˗/˗) mice.6–9 Initial reports showed that BACE1˗/˗
mice were viable and fertile and did not have detectable
abnormalities. Their normal morphology and behavior, tissue
histology, and blood cell and clinical chemistry characteristics
suggested that BACE1 inhibition as a therapeutic approach
for AD might lack mechanism-based toxicities. Additionally,
APP-overexpressing transgenic mice that also lack the BACE1
gene are devoid of cerebral Aβ, amyloid deposition, and
Aβ-associated memory impairments.10–14 It is important to note
that these data validate BACE1 as the major β-secretase in the
CNS and indicate that BACE2 does not compensate for BACE1
loss of function, at least for the production of Aβ. Furthermore,
they strongly suggested that BACE1 inhibition should be a safe
and effective therapeutic strategy for AD.
Although initial studies of BACE1˗/˗ mice indicated that
BACE1 was not required for viability in vivo, further investi-
gations were necessary to elucidate the physiological functions
of BACE1 and to fully understand the potential for mechanism-
based toxicities of therapeutic BACE1 inhibition. For example,
BACE1 protein is highly concentrated in presynaptic terminals
of CNS neurons, suggesting that BACE1 has a role in
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synaptic function. Moreover, in agreement with high BACE1
expression and presynaptic localization in neurons, deeper
analyses of BACE1˗/˗ mice have uncovered numerous subtle
neuronal phenotypes, such as axon targeting errors, reduced
myelination, memory impairments, reduced muscle spindles,
neurochemical abnormalities, alterations in neurogenesis and
astrogenesis, increased age-related neurodegeneration, reduced
spine density, retinal pathology, endophenotypes of schizophre-
nia, and seizures. Future investigations may reveal even more
BACE1-null phenotypes. Any of these BACE1-null phenotypes
in theory could represent mechanism-based side effects of
BACE1 inhibitor drugs in humans, thus raising a note of
caution that therapeutic inhibition of BACE1 might not be
completely free of toxicity.
2.2. Substrates of BACE1
The varied phenotypes of the BACE1˗/˗ mice are likely the
result of abrogated β-secretase processing of different sub-
strates of BACE1 in addition to APP. Recent proteomic analyses
in cultured primary neurons have identified numerous putative
BACE1 substrates that have roles in neuronal functions.15,16 The
majority of substrates of BACE1 are, like APP, type I membrane
proteins, and a few, like neuregulin 1 (NRG1), have more
complex membrane topologies. Cleavage of most substrates by
BACE1 releases an ectodomain fragment that diffuses from the
cell in the extracellular milieu. There, it may bind to another
molecule on the same (autocrine) or a different (paracrine) cell
to affect signal transduction or cell-cell interactions. Perhaps
the best-studied example is that of BACE1 processing of type
III NRG1, which releases an epidermal growth factor–like
domain that binds to the ErbB receptor on the Schwann cell
for the stimulation of myelination. Because of the lack of
β-secretase processing, BACE1˗/˗ mice have decreased shed-
ding of the NRG1 epidermal growth factor domain, which
reduces instructive signals to myelinating cells and leads to
hypomyelination.
Another example of β-secretase processing of a neuronal
substrate involves the cleavage of the neural cell adhesion
molecule close homologue of L1 (CHL1) by BACE1. Like
APP, CHL1 is a type I membrane protein, and it has a well-
known function in axonal outgrowth and neuronal survival.
Cleavage of CHL1 by BACE1 liberates a soluble ectodomain
fragment that may bind to neuropilin-1 and semaphorin 3A, 2
molecules that are involved in axonal guidance. Thus, the lack
of β-secretase processing of CHL1 might account for the pres-
ence of mistargeted axons that have been reported in the olfac-
tory bulb and hippocampus of BACE1-null mice.15–17
In addition to cleavage by BACE1, a number of BACE1 sub-
strates undergo ectodomain shedding by proteases in the A
disintegrin and metalloproteinase domain (ADAM) family. The
extent to which a given substrate is processed by BACE1 versus
an ADAM family member varies depending on the substrate.
Some substrates are almost exclusively cut by BACE1 (e.g.,
SEZ6, APLP1), whereas other substrates are primarily cleaved by
the ADAMs (e.g., APP, neuroligin-1). One would predict from
these results that potential mechanism-based side effects that
arise from therapeutic BACE1 inhibition might derive from
deficient processing of substrates that predominantly undergo
ectodomain shedding by BACE1 rather than the ADAMs. Con-
versely, potential toxicities of BACE1 inhibition may be less
associated with substrates that are primarily cleaved by ADAM
proteases over BACE1.
2.3. BACE2˗/˗ mice
The significant amino acid similarity shared by BACE1 and
BACE2 suggests that it may be challenging to develop BACE1
inhibitors that do not cross-inhibit BACE2. Therefore, the pos-
sibility exists that BACE1 inhibitor drugs might also cause
BACE2 mechanism-based side effects in addition to those of
BACE1. To investigate this question, BACE2˗/˗ mice were pro-
duced by gene targeting. Like BACE1-null mice, the BACE2˗/˗
mice were initially shown to be viable and fertile with no
reported phenotype.9 Moreover, other than enhanced early post-
natal lethality, BACE1˗/˗ BACE2˗/˗ double knockout mice did
not have a more severe phenotype than the BACE1˗/˗ single
knockouts.9 These data suggest that cross-inhibition of BACE2
with BACE1 inhibitors might not be associated with enhanced
toxicity in the adult after postnatal development is completed.
Although BACE2˗/˗ mice initially were reported to be
normal, further investigations have revealed BACE2 loss-of-
function phenotypes. Pancreatic β-cells express significant
levels of BACE2. Interestingly, BACE2˗/˗ mice have increased
β-cell mass and insulin levels, and the mice exhibit enhanced
glucose regulation.18 These phenotypes appear to be the result
of abrogated BACE2 cleavage of proproliferative type I trans-
membrane protein Tmem27, a protein involved in the regula-
tion of β-cell mass. Given these results, inhibition of BACE2
may be beneficial for the treatment of type 2 diabetes, although
further research into this hypothesis is necessary.
In addition to the pancreatic phenotype, BACE2˗/˗ mice
on a C57BL/6 genetic background exhibit hypopigmentation
that results in a silvery coat, compared with the dark coat
of wild-type C57BL/6 mice. This phenotype is caused by lack
of BACE2 processing of the melanocyte protein PMEL, which
is expressed in pigment cells of the skin and eye. BACE2
cleavage releases a fragment of PMEL into melanosomes that
forms a matrix of amyloid fibrils upon which melanin is
deposited.19 Consequently, abrogated processing of PMEL in
BACE2˗/˗ mice leads to abnormal melanosome formation and
hypopigmentation. These results suggest the possibility that
cross-inhibition of BACE2 by BACE1 inhibitors might cause
reduced pigmentation in humans.
3. Small-molecule BACE1 inhibitor drugs and clinical
trials for AD
The extensive validation of BACE1 as the primary
β-secretase enzyme in the CNS has spurred vigorous efforts to
develop small-molecule inhibitors of BACE1 in both academia
and industry. The first generation of BACE1 inhibitors con-
sisted of noncleavable peptide-based transition state analogues
designed after the amino acid sequence in APP at which
β-secretase cleaves. Typically, these large peptidomimetic mol-
ecules are very potent BACE1 inhibitors in vitro, mainly
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because the large open active site of BACE1 has evolved to bind
polypeptide substrates with high affinity. Unfortunately, the
peptide-based BACE1 inhibitors did not possess favorable in
vivo pharmacologic properties, such as oral bioavailability, long
serum half-life, or blood-brain barrier (BBB) penetration. As a
consequence, investigators have turned toward designing true
small-molecule BACE1 inhibitor drugs. However, the develop-
ment of nonpeptidic BACE1 inhibitors large enough to bind
with sufficient affinity to the enzymatic active site, yet small
enough to exhibit satisfactory pharmacokinetics and suitable
brain penetration, has proven to be very challenging. Moreover,
BACE1 inhibitors should have sufficient lipophilicity to cross
both plasma and endosomal membranes for gaining access to
the vesicle lumen where the BACE1 active site is located.
A crucial advance in small-molecule BACE1 inhibitor
development came with the first X-ray co-crystal structure of
BACE1 with a peptidic BACE1 inhibitor.20 The BACE1 X-ray
structure revealed important inhibitor-enzyme interactions
that were exploited in rational drug design efforts. Shortly
thereafter, new classes of small-molecule BACE1 inhibitors
were developed that exhibited improved pharmacologic char-
acteristics, including small molecular weight, plasma mem-
brane permeability, and better pharmacokinetics. However,
most second-generation BACE1 inhibitors were substrates of
P-glycoprotein, the adenosine triphosphate-dependent drug
efflux pump for xenobiotics in the BBB, and therefore could not
reach high concentrations in the brain.
More recently, potent third-generation small-molecule
BACE1 inhibitors have been developed that achieve satisfactory
brain penetration and robust cerebral Aβ reduction in preclinical
animal models. Innovative diverse and complex drug develop-
ment approaches have been employed to design current BACE1
inhibitors. For example, in fragment-based approaches, small
molecules are screened from libraries of compounds that exhibit
brain penetration and other favorable druglike properties and are
selected for BACE1 binding and enzyme inhibition in vitro. Hits
of the screen are then co-crystalized with BACE1, and X-ray
structures are determined. Small molecules exhibiting weak
interactions with the BACE1 active site are bonded together to
form larger molecules that strongly bind and inhibit BACE1 yet
still retain favorable brain penetration and drug properties.
These approaches have yielded several orally bioavailable
BACE1 inhibitor drugs that have entered into human clinical
trials. Several compounds are in late clinical phases, including
those from Merck, AstraZenica, Eisai, Jannsen, Novartis,
among others. Expected trial completion dates range from 2017
to 2024. Although scant information on their progress has been
published, preliminary trial results for several BACE1 inhibitor
drugs have been reported at recent conferences and indicate that
these compounds cross the BBB, robustly inhibit Aβ production
in cerebrospinal fluid, and appear to be well tolerated. However,
we do not yet know whether they will be safe and effective for
the treatment or prevention of AD.
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